Capital Increase in Genmab as a Result of Employee Warrant Exercise
September 18 2018 - 12:16PM
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement
Copenhagen, Denmark; September 18, 2018 –
Genmab A/S (Nasdaq Copenhagen: GEN) will increase its share
capital by 18,414 shares as a consequence of the exercise of
employee warrants.
The increase is effected without any preemption rights for the
existing shareholders of the company or others. The shares are
subscribed in cash at the following price per share of nominally
DKK 1:
5,000 shares at DKK 174.00,2,000 shares at DKK 199.00,1,750
shares at DKK 210.00,50 shares at DKK 215.60,3,250 shares at DKK
225.90,1,500 shares at DKK 234.00,900 shares at DKK 234.75,3,063
shares at DKK 272.00,563 shares at DKK 337.40, and338 shares at DKK
466.20
Proceeds to the company are approximately DKK 4.12 million. The
increase corresponds to approx. 0.03 % of the company's share
capital.
The new shares are ordinary shares without any special rights
and are freely transferable negotiable instruments. The new shares
give rights to dividends and other rights in relation to the
company as of subscription, i.e. inter alia full rights to
dividends for the financial year 2018. The new shares will be
listed on Nasdaq Copenhagen after registration with the Danish
Business Authority. The capital increase is expected to be
finalized shortly.
Pursuant to section 32 of the Danish Capital Markets Act No 12
of January 8, 2018, it is hereby announced, that the total nominal
value of Genmab A/S' share capital after the capital increase is
DKK 61,489,983, which is made up of 61,489,983 shares of a nominal
value of DKK 1 each, corresponding to 61,489,983 votes.
About Genmab Genmab is a publicly traded,
international biotechnology company specializing in the creation
and development of differentiated antibody therapeutics for the
treatment of cancer. Founded in 1999, the company has two
approved antibodies, DARZALEX® (daratumumab) for the treatment of
certain multiple myeloma indications, and Arzerra® (ofatumumab) for
the treatment of certain chronic lymphocytic leukemia
indications. Daratumumab is in clinical development for
additional multiple myeloma indications and other blood
cancers. A subcutaneous formulation of ofatumumab is in
development for relapsing multiple sclerosis. Genmab also has
a broad clinical and pre-clinical product pipeline. Genmab's
technology base consists of validated and proprietary next
generation antibody technologies - the DuoBody® platform for
generation of bispecific antibodies, and the HexaBody® platform
which creates effector function enhanced antibodies. The
company intends to leverage these technologies to create
opportunities for full or co-ownership of future products. Genmab
has alliances with top tier pharmaceutical and biotechnology
companies. For more information visit www.genmab.com.
Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations
& CommunicationsT: +45 33 44 77 20; M: +45 25 12 62 60; E:
rcg@genmab.com This Company Announcement contains forward looking
statements. The words “believe”, “expect”, “anticipate”, “intend”
and “plan” and similar expressions identify forward looking
statements. Actual results or performance may differ materially
from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual
results or performance to differ materially include, among others,
risks associated with pre-clinical and clinical development of
products, uncertainties related to the outcome and conduct of
clinical trials including unforeseen safety issues, uncertainties
related to product manufacturing, the lack of market acceptance of
our products, our inability to manage growth, the competitive
environment in relation to our business area and markets, our
inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and
proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our
products obsolete, and other factors. For a further discussion of
these risks, please refer to the risk management sections in
Genmab’s most recent financial reports, which are available on
www.genmab.com. Genmab does not undertake any obligation to update
or revise forward looking statements in this Company Announcement
nor to confirm such statements to reflect subsequent events or
circumstances after the date made or in relation to actual results,
unless required by law. Genmab A/S and/or its subsidiaries own the
following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in
combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®;
DuoBody in combination with the DuoBody logo®; HexaBody®; HexaBody
in combination with the HexaBody logo®; and UniBody®. Arzerra® is a
trademark of Novartis AG or its affiliates. DARZALEX® is a
trademark of Janssen Pharmaceutica NV.
Company Announcement no. 27CVR no. 2102 3884LEI Code
529900MTJPDPE4MHJ122
Genmab A/SKalvebod Brygge 431560 Copenhagen VDenmark
- 27_2018.09.18 CA_Warrant Exercise